Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Epizyme, Inc. | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Epizyme, Inc.

Mikel Moyer, Ph.D., has been named vice president of Molecular Discovery at Epizyme, Inc.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mikel Moyer, Ph.D., has been named vice president of Molecular Discovery at Epizyme, Inc. He joins the company from the Broad Institute, where he was director of Medicinal Chemistry in the Stanley Center for Psychiatric Research. Prior to that, Dr. Moyer held leadership positions in medicinal chemistry groups at Pfizer for almost 20 years.

“Mike is a recognized leader in molecular discovery, and I welcome him to Epizyme, where his contributions will significantly advance our development of first-in-class medicines targeting histone methyltransferases (HMTs), a key group of epigenetic enzymes,” said Robert A. Copeland, Ph.D., executive vice president and chief scientific officer of Epizyme. “Mike’s appointment completes our highly experienced research leadership team, where he joins Dr. Victoria Richon, our vice president of Biological Sciences. Vicky led the team that discovered Zolinza at Memorial Sloan Kettering and was a co-founder of Aton, which was subsequently acquired by Merck.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics